Department of Internal Medicine, University of Ioannina, Ioannina, Greece.
Eur J Pharmacol. 2010 May 10;633(1-3):62-70. doi: 10.1016/j.ejphar.2010.02.003. Epub 2010 Feb 10.
Ezetimibe represents a new lipid lowering agent which inhibits cholesterol absorption. It effectively reduces low-density lipoprotein cholesterol when administered either alone or in combination with statins. However, its effect on cardiovascular mortality remains under question since it failed to demonstrate any significant changes in the primary endpoints of the recently published ENHANCE and SEAS studies. A possible explanation for this unsuccessful outcome is that ezetimibe lacks pleiotropic effects. This article aims to review the potential pleiotropic effects of the drug mainly on inflammation markers, lipoprotein subfractions and endothelial function.
依泽替米贝是一种新型降脂药物，可抑制胆固醇吸收。该药单独或与他汀类药物联合应用均能有效降低 LDL-C。然而，由于最近发表的 ENHANCE 和 SEAS 研究主要终点并未显示出任何显著变化，其对心血管死亡率的影响仍存在疑问。这种结果不理想的可能原因是依泽替米贝缺乏多效性作用。本文旨在综述该药在炎症标志物、脂蛋白亚组分和内皮功能方面的潜在多效性作用。
